Ditiocarb-d10
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ditiocarb-d10
Description :
Ditiocarb-d10 (Diethyldithiocarbamic acid-d10) is the deuterium labeled Ditiocarb (HY-126363) [1]. Ditiocarb (Diethyldithiocarbamic acid) is an accelerator of the rate of copper cementation. Ditiocarb (Diethyldithiocarbamic acid) reduces the incidence of HIV infection, and also enhances adjuvant immunoresearch of high risk breast cancer[2][3][4].Product Name Alternative :
Diethyldithiocarbamic acid-d10UNSPSC :
12352211Target :
HIV; Isotope-Labeled CompoundsType :
Isotope-Labeled CompoundsRelated Pathways :
Anti-infection; OthersField of Research :
InfectionSolubility :
10 mM in DMSOSmiles :
S=C(S)N(C([2H])([2H])C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])[2H]Molecular Formula :
C5HD10NS2Molecular Weight :
159.34References & Citations :
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41 (4) :289-293.|[3]Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265 (12) :1538-44.|[4]Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6 (1) :9-12.Shipping Conditions :
Room temperatureScientific Category :
Isotope-Labeled CompoundsClinical Information :
No Development ReportedCAS Number :
[1261734-83-1]

